Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 05, 2021 at 05:00 am EDT
Share
Editas Medicine, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 56.883 million compared to USD 46.616 million a year ago. Net loss was USD 56.728 million compared to USD 37.724 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.69 a year ago.
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
EDITAS MEDICINE, INC. 
